EVO Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Q4 2025 Revenues: Increased by EUR 32.1 million (14.5%) to EUR 253.3 million; full-year revenues decreased by EUR 8.6 million (1.1%) to EUR 788.4 million.
Constant Currency Growth: Q4 revenues grew by 21%; full-year revenues grew by 1.7%.
Just-Evotec Biologics (JEB): Revenues surged by EUR 59.4 million (104.2%) in Q4 and EUR 73.8 million (39.8%) for the full year, driven by the Sandoz partnership.
Discovery and Preclinical Development (D&PD): Revenues declined by EUR 27.3 million (16.6%) in Q4 and EUR 82.5 million (13.5%) for the full year.
Adjusted EBITDA: Increased by EUR 29.5 million (103.6%) to EUR 58 million in Q4; full-year adjusted EBITDA rose by EUR 18.5 million (81.9%) to EUR 41.1 million.
Cash Position: Ended 2025 with EUR 476 million in cash liquidity and no active financial covenants.

2. Strategic Updates and Business Highlights

New Strategy: Introduced a strategy focusing on scientific leadership, operational excellence, better monetization of JEB, and capturing pipeline value.
Cost Savings: Achieved over EUR 60 million in annualized cost savings and reduced capital expenditure by approximately 60%.
Horizon Initiative: Launched to transform operations, with expected structural and financial benefits in the second half of 2026.
Key Partnerships: Continued progress in collaborations with Bristol Myers Squibb (BMS) in oncology and neurodegeneration, leading to significant milestone payments.
JEB Transformation: Shifted to a technology-focused partner enablement model, highlighted by a strategic agreement with Sandoz valued at $650 million.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Projected group revenues of EUR 700 million to EUR 780 million; adjusted EBITDA expected to range from EUR 0 million to EUR 40 million.
Market Recovery: Anticipated improvement in the second half of 2026, driven by strategic partnerships and a recovery in the early-stage drug discovery market.
D&PD Segment: Expected low single-digit growth in the second half of 2026, with a focus on strategic technology-driven partnerships.

4. Bad News, Challenges, or Points of Concern

Revenue Declines: D&PD segment faced significant revenue declines, indicating challenges in early-stage biotech funding.
BMS Collaboration: Revenue from BMS is expected to decline by high single digits in 2026, marking a trough year.
Operational Risks: The Horizon initiative involves cutting 800 positions and consolidating sites, raising concerns about potential customer disruption and talent loss.
Market Conditions: The early-stage drug discovery market remains challenging, with continued softness impacting revenue generation.

5. Notable Q&A Insights

Growth in Non-Sandoz Business: Non-Sandoz, non-Department of War revenues in JEB are expected to reach about 50% of overall JEB revenues by the end of 2026, up from approximately 30% in 2025.
BMS Future Payments: The collaboration is shifting towards more milestone and royalty-based remuneration, with expectations of continued payments as assets progress.
AI Integration: There is growing interest in AI-driven solutions from both pharma and biotech partners, presenting opportunities for JEB.
Horizon Implementation Timeline: Site closures and workforce reductions will begin in Q4 2026, subject to local regulations and negotiations.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Evotec's performance and outlook.

EVO — Evotec SE